HTB

IAS 5 Cape Town 2009

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-23 July 2009, Cape Town

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention abstracts

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-23 July 2009, Cape Town

First results of new integrase compound: GSK1349572

Raltegravir in treatment-naive patients

Nevirapine vs atazanavir/ritonavir in treatment-naive patients: ARTEN study

Darunavir/r monotherapy studies

Maraviroc results similar to efavirenz when analysed using more sensitive tropism test

Lipid and metabolic changes with ARV combinations

Maximal suppression achieved with three drugs: no additional virological impact of raltegravir intensification

Tenofovir and renal safety

Time from seroconversion to treatment in Europe and Africa

Pharmacokinetics of atazanavir/ritonavir during pregnancy

Presentation with late stage HIV in women diagnosed during pregnancy

Low transmission rates and favourable pregnancy outcomes reported in the DREAM study

Pregnancy rates and outcomes among women in the DART trial

Pregnancy outcomes in HAART exposed infants in Johannesburg

Efavirenz conceptions in Soweto

Impact of regimen and duration of therapy on risk of mother-to-child HIV transmission in Johannesburg

A cost-effectiveness analysis of the OCTANE trial

The PEARL study

Results from HSV-2 acyclovir studies

Overview of TB-related studies at IAS

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention abstracts

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-23 July 2009, Cape Town

Five-year survival rates of 87% without routine CD4 or laboratory monitoring in DART study demonstrate an important model for ARV access programmes

Biomarkers associated with mortality: long-term follow up from SMART

Update on Interleukin-2 clinical trials

Influenza vaccine effective in HIV-positive adults

Reducing HIV transmission during breastfeeding

Treating children previously exposed to single dose nevirapine